Home / Healthcare/ Sanofi tests three-in-one antibody to treat or prevent HIV

Sanofi tests three-in-one antibody to treat or prevent HIV


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 27 September 2017 00:00


London (Reuters): A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys.

Plans are under way to try the so-called trispecific antibody in initial human trials before the end of 2018, potentially adding a new weapon in the fight against AIDS, assuming the product proves safe and effective.

If all goes well, the three-in-one antibody could be used either as a long-acting treatment or a vaccine, according to Sanofi Chief Scientific Officer Gary Nabel.

“There is certainly urgency for a vaccine and this could help fill that void,” he said in an interview. “But we need to do the clinical studies and let nature tell us what works.”

Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, whose experts collaborated on the project, described the new approach as “intriguing”.

Unlike naturally occurring antibodies, the laboratory-made ones hit multiple biological targets in a single product - a feature that is particularly valuable in fighting HIV, given the huge genetic diversity of viruses around the world.

After exposing 24 monkeys to two strains of a monkey form of HIV, researchers found the majority of those given a traditional antibody developed infection compared with none of those receiving the trispecific one.

The results were published in the journal Science on Wednesday.

Other experiments showed the novel antibodies were active against 99 percent of more than 200 diverse strains of HIV tested.

The ability of trispecific antibodies to hit three targets at once might also make them useful in fighting cancer, other infectious diseases and autoimmune diseases. A number of drug companies are already working with bispecific antibodies but a three-pronged approach takes things to the next level.

“This is the beginning of a technology platform that we could adapt to other diseases, so we will look carefully at that,” Nabel said.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Bright star Imran Khan could well go the way of his predecessors

Saturday, 21 July 2018

Imran Khan, the Pakistani cricket star, anti-corruption crusader and politician, appears to be within reach of his cherished goal of winning the 25 July Pakistan National Assembly (NA) elections and becoming Prime Minister.


Top Cola brand crashing globally; lesson for Sri Lanka

Friday, 20 July 2018

We have heard the age old adage, if a brand is not in line to the trends of a customer, they will cease to exist over time.


Religion and politics: a tale of two hypocrisies

Friday, 20 July 2018

It was the best of times, it was the worst of times; it was the age of wisdom, it was the age of foolishness; it was the epoch of belief,


Sri Lanka’s Trade Information Portal – Bringing local traders one step closer to the global market

Friday, 20 July 2018

Sri Lanka’s traditional lacework famously known as Beeralu is slowly moving into the spotlight of the global fashion industry


Columnists More